ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02970942
Recruitment Status : Active, not recruiting
First Posted : November 22, 2016
Last Update Posted : October 25, 2018
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : November 27, 2019
  Estimated Study Completion Date : April 2, 2020